Skip to main content
Clinical Trials/DRKS00022991
DRKS00022991
Recruiting
Not Applicable

Immune cell profiles in the blood in children, adolescents and adults with tuberous sclerosis complex disease and their correlation with organ manifestations and treatment response to immunotherapy with mTOR inhibitors

niversitätsklinikum Münster0 sites90 target enrollmentSeptember 23, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Q85.1
Sponsor
niversitätsklinikum Münster
Enrollment
90
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 23, 2020
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
niversitätsklinikum Münster

Eligibility Criteria

Inclusion Criteria

  • Children and adults; clinically and / or molecular\-genetic (from the blood) confirmed tuberous sclerosis with epilepsy.
  • Control group: epilepsy without evidence of tuberous sclerosis; People with no evidence of a neurological disease

Exclusion Criteria

  • Current immunotherapy except mTOR inhibitor therapy (everolimus, sirolimus) (control group of healthy people and people with epilepsy without tuberous sclerosis: also excluded when taking everolimus, sirolimus); current infection; comorbid autoimmune disease

Outcomes

Primary Outcomes

Not specified

Similar Trials